Mortalidad y Morbilidad en pacientes con coinfección TB-VIH/COVID-19. Una revisión Sistemática.

Abstract

ABSTRACT Introduction: The binominal HIV and Tuberculosis is associated with high morbility and mortality in patients with this pathology due to the COVID-19. Hence, patient with HIV the antiretroviral in patients had to be interrupted. In patients with Tuberculosis (TB) the promotion and prevention health program had been limited, consequently, the world health system has seen great deal of demand and problems. Objective: To systematize the scientific evidence available bout the mortality and morbidity in patients re-infected with TB-HIV/VOVID-19. Methodology: This systematic review study was conducted through the interpretation of complete scientific papers published both in English and Spanish from 2017 and 2021 of open access, using the PRISMA method and the searching engines Scopus, Google Scholar and the health virtual library. Results: The coinfection VIV-COVID-19 and TB-COVID-19 represents an imminent risk of the morbidity and mortality rate, but at the moment there are no records about the mortality rate mortality rate from triple infection, although due to carelessness prevention programs and health promotion on HIV and TB, the morbidity and mortality rate has increased, at the level of HIV by 2.75%, while at the level of Tuberculosis by 2.58%. Conclusion: The impact of COVID-19 in patients with HIV and Tuberculosis is uncertain, because there have been no cases of triple infection, so the exact percentage of mortality due to this triple coinfection cannot be specified. Keywords: morbidity, coinfection, Tuberculosis, VIH, COVID-19.